References: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12]
We can't stress this enough: the quality of your results is directly tethered to the quality of your preparation
Two recent individual participant data meta-analyses of RCTs [19, 20] found that the effects of SGLT2 inhibitors and GLP-1 RAs on cardiovascular and kidney outcomes are consistent regardless of the background use of a GLP-1 RA or an SGLT2 inhibitor, respectively [19, 20]
In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise
DNP, an industrial chemical that was marketed for weight loss in the 1930s, even though it caused dehydration, cataracts, liver damage, and death
Who should consider taking liposomal glutathione